Baxiva, Zürich, Switzerland
https://www.baxiva.com/

Baxiva is developing multivalent glycoconjugate vaccine to prevent extraintestinal pathogenic Escherichia coli (ExPEC) infections.

Escherichia coli is the leading cause of urinary tract infections, a frequent cause of neonatal sepsis, and is among the leading causes of antimicrobial resistance-associated deaths globally. Multivalent vaccines are designed to prevent infections caused by multiple strains or types of a single pathogen. The glycoconjugate formulation combines polysaccharide (sugar) from a pathogen’s surface with a carrier protein to enhance immune response and therefore the effectiveness of the vaccine.

Baxiva’s proprietary conjugation platform streamlines the development of multivalent vaccines targeting the serotype-specific polysaccharides of Gram-negative bacteria, including capsule and O antigens. The multivalent vaccine targets the most common serotypes associated with invasive ExPEC infections.

Current Development Stage: Hit to Lead

CARB-X Investment: US$3 million

Initial CARB-X Investment Date: August 21, 2025